Loading patent…
AssigneeSylentis S.A.U.
InventorsAna Isabel Jimenez, Covadonga Pañeda, Tamara Martinez
Estimating the term…
The invention relates to si RNA molecules and their use in methods and pharmaceutical compositions for inhibiting the expression of the NRARP gene. The invention also relates to the use of said si RNAs molecules in the treatment and/or prevention of a disease or disorder related to neovascularization characterised by increased expression and/or activity of NRARP gene, said eye condition is selected from the group comprising age-related macular degeneration (AMD), ischemic retinopathy, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), diabetic retina ischemia (DRI), diabetic retinal edema (DRE) and retinopathy of prematurity (ROP) and combinations thereof.
A method of treating an eye condition characterized by increased expression and/or activity of NRARP in a subject in need thereof comprising administering to the subject a siRNA molecule that specifically targets at least one sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 9, wherein said siRNA comprises a 19- to 28-nucleotide double-stranded structure and wherein said siRNA comprises at least one sequence selected from the group consisting of SEQ ID NO. 10 to SEQ ID NO. 66.
A siRNA molecule wherein said molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 9 and reduces expression of NRARP gene when introduced in a cell and wherein said siRNA comprises a 19- to 28-nucleotide blunt-ended double-stranded structure, wherein said siRNA comprises at least one sequence selected from the group consisting of SEQ ID NO. 10 to SEQ ID NO. 66.
A siRNA molecule wherein said molecule specifically targets at least one sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 9, wherein said siRNA comprises a 19- to 28-nucleotide structure and wherein said siRNA comprises at least one sequence selected from the group consisting of SEQ ID NO. 10 to SEQ ID NO. 66.
Dependencies are inferred from the claim text.